Menu
Back to User profile » Dr Arun Singh
Papers published by Dr Arun Singh:
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
Giron‐Hernandez C, Han JH, Alberio R, Singh A, García-Portilla MP, Pompili M, Knight RK, Richarz U, Gopal S, Antunes J
Neuropsychiatric Disease and Treatment 2023, 19:895-906
Published Date: 13 April 2023
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, Joshi K, Singh A, Godet A, Pungor K, Gopal S
Patient Preference and Adherence 2021, 15:2239-2248
Published Date: 2 October 2021
Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S
Patient Preference and Adherence 2020, 14:1093-1102
Published Date: 2 July 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Neuropsychiatric Disease and Treatment 2020, 16:1533-1542
Published Date: 19 June 2020
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Neuropsychiatric Disease and Treatment 2020, 16:681-690
Published Date: 6 March 2020